Four Genes Predict High Risk of Progression From Smoldering to Symptomatic Multiple Myeloma (SWOG S0120)

Haematologica - Italy
doi 10.3324/haematol.2015.124651
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2019English

Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Hematology/Oncology Clinics of North America
OncologyHematology
2007English

Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Current Hematologic Malignancy Reports
Cancer ResearchOncologyHematology
2010English

The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective

Oncologist
Cancer ResearchMedicineOncology
2016English

Smoldering Multiple Myeloma: Prevalence and Current Evidence Guiding Treatment Decisions

Blood and Lymphatic Cancer: Targets and Therapy
2018English

Baseline Mutational Patterns and Sustained MRD Negativity in Patients With High-Risk Smoldering Myeloma

Blood advances
Hematology
2017English

High-Risk Multiple Myeloma: Different Definitions, Different Outcomes?

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients With Asymptomatic Myeloma at High Risk for Progression to Symptomatic Disease

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2012English

A Phase II Trial of Pan-Kir2d Blockade With IPH2101 in Smoldering Multiple Myeloma

Haematologica
Hematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy